Molecular immunohematology refers to the detection of the molecular genetic basis of an antigen, rather than the antigen alone. Use of molecular testing in clinical laboratories requires knowledge of the molecular basis of blood group antigens and the availability of suitable genotyping methods that can be used in our testing environment.
Immune globulin (Ig) products are generated from plasma collected from a large number of carefully screened donors. Ig products may be used as replacement therapy for immunodeficiency patients or as immunomodulatory therapy for autoimmune and alloimmune disorders. Ig products include intravenous Ig (IVIg), subcutaneous Ig (SCIg), RhD Ig (RhIg) and hyperimmune globulins.
Authors: Sophie Chargé, PhD, and Kendra Hodgkinson, PhD
Online publication date: January 2017
What is blood?
With every heartbeat, about five litres of blood are pumped through your body.
Blood flows through thousands of kilometres of blood vessels, delivering oxygen and nutrients to the organs and carrying waste products away. Blood also transports cells, hormones and proteins that regulate many body functions, such as fighting infection and controlling blood loss.
In August 2017, Canadian Blood Services changed its platelet product testing procedure to improve the detection of bacterial contamination. This change enhanced the safety of Canadian Blood Services platelet products and provided the opportunity to improve inventory management by extending the platelet shelf life from five to seven days.
“Paying it Forward: Why we need YOU to give blood" is an article by Dr. Jeannie Callum, a hospital-based transfusion specialist. Here she shares her real-life experience witnessing the impact of blood donation on patient lives. She provides some fascinating insight into blood transfusion, past and present, and emphasizes the need for male donors and why some donors may be safer for patients. This article is also being published in six parts on RED, our Research, Education and Discovery blog.
Current recommendations of the NAC indicate that the provision of CMV-seronegative and leukoreduced blood products is potentially required only in the setting of intrauterine transfusion. In October 2017, Canadian Blood Services will stop the testing donor blood for anti-CMV antibodies except for a small inventory of blood components tested for the sole purpose of intrauterine transfusion.